Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

Lina Han, Qi Zhang, Monique Dail, Ce Shi, Antonio Cavazos, Vivian R. Ruvolo, Yang Zhao, Eugene Kim, Mohamed Rahmani, Duncan H. Mak, Sha S. Jin, Jun Chen, Darren C. Phillips, Paul Bottecelli Koller, Rodrigo Jacamo, Jared K. Burks, Courtney DiNardo, Naval Daver, Elias Jabbour, Jing Wang, Hagop M. Kantarjian, Michael Andreeff, Steven Grant, Joel D. Leverson, Deepak Sampath, and Marina Konopleva

Disclosures: This work was supported in part by AbbVie and Genentech, the NIH/NCI through The MD Anderson Cancer Center Support Grant (P30 CA016672), a Shared Instrumentation Award from the Cancer Prevention Research Institution of Texas (CPRIT; RP121010), and CA167708, UH2TR001373, CA205607 (to Dr. S Grant)

Contributions: LH designed the study, performed experiments, analyzed the data, and wrote the manuscript; QZ, CS, AC, VRR, MR, JC, and SSJ performed experiments; MD analyzed the data and provided advices on experimental design; YZ, JW and EK performed the statistical analysis; DHM, RJ and JKB provided technical supports; CD, ND, EJ, HMK, MA provided advice on experimental design; PBK, DS, JDL, SG and DCP provided advice on experimental design and reviewed and commented the manuscript; MK oversaw the project, designed the study, interpreted data, and wrote the manuscript.